
	Where results make sense

Topic: Biogen Idec

Related Topics

Avonex

Research Triangle Park, North Carolina

Becton Dickinson

Alza

Amgen

Diosynth

Abbott Laboratories

Genentech

Gilead Sciences

PACCAR

List of pharmaceutical companies

Akzo Nobel

Verizon

Pharmaceutical

Massachussetts

	Biogen Idec - Wikipedia, the free encyclopedia
		Biogen Idec is a member of the SandP 500, SandP 1500, and NASDAQ-100.
		Biogen is headquartered in Kendall Square in Cambridge, Massachusetts, and operates research and development facilities in Cambridge and San Diego.
		Biogen Idec maintains its international headquarters in Zug, Switzerland, and operates an International regulatory and clinical center of excellence in Maidenhead, UK.
	en.wikipedia.org /wiki/Biogen_Idec (760 words)

	Biogen Idec profits drop 26% - The Boston Globe
		Biogen Idec Inc.'s third-quarter profits dropped 26 percent compared to the previous year amid charges from its 2003 merger and expenses from a layoff begun in September.
		Biogen and its Irish partner, Elan Corp., withdrew Tysabri and disclosed the drug may heighten the risk of contracting a rare disease of the central nervous system.
		Biogen Idec predicted it would generate earnings per share next year, excluding unusual items, of $1.95 to $2.10, compared to a consensus of Wall Street analysts that predicts the company to generate $1.63 for the current year.
	www.boston.com /business/healthcare/articles/2005/10/27/biogen_idec_profits_drop_26 (455 words)

	[No title] (Site not responding. Last check: 2007-09-19)
		Biogen Idec Inc., Interwiki: nasdaq BIIB is a pharmaceutical company specializing in drugs for autoimmune disorders and cancer.
		Biogen Idec markets Avonex in two formulations: the original powder form, which requires the patient to reconstitute it before administration; and a newer pre-reconstituted "liquid Avonex" syringe kit.
		Biogen Idec is headquartered in Kendall Square in Cambridge, Massachusetts, and operates research and development facilities in Cambridge and San Diego.
	www.worldhistory.com /wiki/B/Biogen-Idec.htm (512 words)

	Biogen Idec's executive chairman to retire this month - The Boston Globe
		Biogen Idec purchased a $1.7 million condominium in a luxury tower in Cambridge for Rastetter to live in when he was in the area, but he avoided publicity and was rarely seen at local biotechnology events.
		Biogen Idec this year said it was selling several key assets that it acquired with Idec, including a new manufacturing plant in Oceanside, Calif., and other West Coast facilities.
		In 2005, Biogen Idec's activities were dominated by Tysabri, the multiple sclerosis drug that was expected to be a blockbuster.
	www.boston.com /business/technology/biotechnology/articles/2005/12/08/biogen_idecs_executive_chairman_to_retire_this_month (660 words)

	BioWorld Today
		Biogen Idec is expected to file another sBLA for Rituxan to treat indolent, front-line and maintenance non-Hodgkin’s lymphoma in the first half of this year, and the FDA’s PDUFA date for the use of Rituxan in rheumatoid arthritis patients who failed anti-TNF therapy is scheduled for Feb. 28.
		Also in the pipeline, Biogen Idec has oral fumarate BG-12 in Phase II development for multiple sclerosis; daclizumab, for the same indication, which is entering a Phase II monotherapy trial this summer; and M200 (volociximab), which should have Phase II solid-tumor data available in June at the American Society of Clinical Oncology meeting.
		Biogen Idec expects its 2006 non-GAAP earnings per share estimates, excluding the impact of stock option expensing, will be in the range of $1.95 to $2.10, and capital expenditures to be between $190 million and $275 million.
	www.bioworld.com /servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=38069 (849 words)

	Biogen Idec - COPENHAGEN CAPACITY, Denmark (Site not responding. Last check: 2007-09-19)
		Biogen Idec expects to invest USD 340 million to build the production facility, which will be one of the largest facilities in the world producing drugs for scleroses and psoriasis.
		Biogen Idec Inc. was formed in 2003 from the merger of the worldâs two leading biotechnology companies, Biogen Inc.
		Biogen Idec expects that Antegen will be approved by the authorities in the US and Europe in the near future.
	www.locations.copcap.com /composite-8316.htm (1057 words)

	biogen idec
		Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing.
		Biogen Idec is dedicated to pursuing the creativity of science.
		Biogen Idec expects to initially invest over $550 million per year in research and development, and has 1,000 RandD employees, including approximately 400 in discovery research.
	www.jobpilot.ch /profile/firmen/biogen_idec (332 words)

	CBS News \| Biogen Idec 3Q Profit Falls 27 Percent
		Biogen Idec said last month that it would cut 650 jobs in a plan to reduce annual expenses by $200 million to $300 million.
		Biogen Idec said it expects a full-year profit next year in the per-share range of $1.95 to $2.10, not counting the effects of stock-option expenses.
		Biogen shares plunged more than 42 percent on Feb. 28, the day Biogen Idec and its Irish partner, Elan Corp., withdrew the MS treatment Tysabri and disclosed the drug may heighten the risk of contracting a rare and often fatal disease of the central nervous system.
	www.cbsnews.com /stories/2005/10/26/ap/business/printableD8DG04U8D.shtml (645 words)

	Biogen Idec: Facts and details from Encyclopedia Topic (Site not responding. Last check: 2007-09-19)
		Biogen Idec is headquartered in Kendall Square Kendall Square quick summary:
		Biogen Idec's principal competitors include Genentech[For more facts and a topic of this subject, click this link] (with which the company has a marketing partnership for the cancer drug Rituxan rituximab quick summary:
		(Biogen Idec and marketing partner Elan Pharmaceuticals[Click link for more facts about this topic] abruptly pulled multiple sclerosis drug Tysabri from the market after three patients involved in a clinical trial were diagnosed with a severe brain condition, EHandler: no quick summary.
	www.absoluteastronomy.com /encyclopedia/b/bi/biogen_idec.htm (706 words)

	Disclaimer - Biogen Idec
		Biogen Idec is not engaged in rendering medical or similar professional services or advice via this website, and the information provided is not intended to replace medical advice offered by a physician.
		You should not construe Biogen Idec’s publication of this content as an endorsement by Biogen Idec of the views expressed herein, or any warranty or guarantee of any strategy, recommendation, treatment, action, or application of medication or preparation made by the author of the content.
		Biogen Idec makes no representation that the information in the website is appropriate or available for use in other locations, and access to the Biogen Idec website from territories where the content of the Biogen Idec website may be illegal is prohibited.
	www.biogen.nl /disclaimer (1177 words)

	Biogen Idec's Rastetter is ready to retire as executive chairman \| The San Diego Union-Tribune
		Biogen Idec's Rastetter is ready to retire as executive chairman
		William H. Rastetter, 57, former CEO of Idec Pharmaceuticals in San Diego, announced that he was resigning as chairman of Biogen Idec at the end of the year.
		In November 2003, the $6.8 billion Biogen Idec merger was finalized, creating the world's third largest biotech.
	www.signonsandiego.com /uniontrib/20051208/news_1b8biogen.html (706 words)

	CNN.com - Idec to buy Biogen for $6.5bn - Jun. 23, 2003
		Idec Pharmaceuticals Corp. Monday said it would pay $6.5 billion in stock to acquire Biogen Inc. in the biggest biotechnology deal in 18 months, merging two companies facing declining sales growth of their blockbuster drugs.
		Idec said the deal, expected to close by the end of the third quarter or early fourth quarter, would improve its earnings within two to three years.
		Shares of Biogen were down $1.95 to $41.85, or 4.5 percent, while Idec fell $1.81 to $37.16, or 4.6 percent, in heavy afternoon trade on the Nasdaq.
	www.cnn.com /2003/BUSINESS/06/23/biogen (653 words)

	ABC News: Biogen Idec CEO Awarded $1.2M Bonus (Site not responding. Last check: 2007-09-19)
		BOSTON Feb 10, 2006 (AP)— Biogen Idec Inc.'s top executive was awarded a $1.2 million bonus and a 10 percent salary increase after a year in which the biotechnology company withdrew a promising drug from the market, leading to job cuts and 32 percent drop in its stock price, according to a regulatory filing Friday.
		Biogen Idec's board this month also awarded James C. Mullen options to buy 240,000 shares of the company's stock and granted another 180,000 shares of restricted stock, according to the filing Friday.
		Biogen Idec spokesman Tim Hunt said Mullen's compensation is based on several performance measures including the company's earnings and stock performance as well progress in bringing new drugs to market.
	abcnews.go.com /Business/wireStory?id=1604890 (418 words)

	Better Times at Biogen IDEC [Fool.com: Commentary] March 11, 2005
		Biogen IDEC and its partner Elan Pharmaceuticals (NYSE: ELN) got rocked so hard by the news that I thought it was worth looking at them again with a different set of assumptions -- most importantly, the assumption that Tysabri will once again be made available to patients.
		In fact, Biogen IDEC's PEG ratio isn't much lower than that of Serono, which right now can only be seen as the beneficiary of the Tysabri debacle.
		The $615 million in revenues Rituxan brought Biogen IDEC in 2004 isn't going to grow enough to satisfy the expectations of investors in a biotech company with a market cap still at nearly $13 billion.
	www.fool.com /news/commentary/2005/commentary05031102.htm (1465 words)

	BostonWorks - Biogen Idec Jobs and Employer Profile (Site not responding. Last check: 2007-09-19)
		In November 2003, Biogen Idec Inc. (NASDAQ: BIIB) was formed from the merger of two of the world's leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation.
		Biogen Idec expects to initially invest over $550 million per year in research and development, and has 1,000 R&D employees, including approximately 400 in discovery research.
		Biogen Idec is headquartered in Cambridge, MA and maintains centers of excellence in San Diego, CA and Cambridge focused on oncology and immunology.
	bostonworks.boston.com /research/profiles/biogen.shtml (359 words)

	Biogen IDEC - Investor Relations
		Biogen Idec pursues the creativity of science with passion and discipline.
		In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale.
		Biogen Idec is headquartered in Cambridge, MA and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in Switzerland in 1978, and IDEC Pharmaceuticals Corporation, founded in San Francisco, CA in 1985.
	investor.biogenidec.com /phoenix.zhtml?c=148682&p=IROL-index (498 words)

	Biogen Idec Legal Disclaimer (Site not responding. Last check: 2007-09-19)
		Biogen Idec makes no representation or warranty that access to the Sites will be available on a timely basis, will be uninterrupted or will be error free.
		Biogen Idec does not warrant that these pages, or the server that makes them available, are free of viruses or other harmful elements.
		In no event shall any of Biogen Idec, its affiliates and subsidiaries, and their respective officers, directors, employees, agents, representatives, information providers and licensors and their respective heirs and assigns, be liable for any direct, indirect, incidental, consequential, exemplary, special, punitive or other damages even if informed of the possibility of such damages.
	www.avonex.com /msavProject/avonex.portal/_baseurl/threeColLayout/SCSRepository/en_US/avonex/includes/footer/legal_disclaimer.xml (1113 words)

	BioWorld Today
		Biogen is paying an initial license fee of $10 million and investing $6 million in Vernalis, with a promise to invest a further $4 million in any future Vernalis fund raising.
		Biogen Idec, of Cambridge, Mass., is buying 6.2 million shares at 53 pence per share, representing about 4.2 percent of Reading, UK-based Vernalis.
		Biogen Idec has exclusive rights to the lead compound V2006, which recently completed a Phase I single-ascending-dose study.
	www.bioworld.com /servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=33122 (540 words)

	WTOP: Biogen Idec CEO Awarded $1.2M Bonus
		BOSTON (AP) - Biogen Idec Inc.'s top executive was awarded a $1.2 million bonus and a 10 percent salary increase after a year in which the biotechnology company withdrew a promising drug from the market, leading to job cuts and 32 percent drop in its stock price, according to a regulatory filing Friday.
		Biogen Idec's third-quarter profit fell by 27 percent, partly due to severance expenses from the job cuts.
		But Biogen Idec and its Irish drug development partner Elan Corp. withdrew Tysabri on Feb. 28, 2005, and disclosed the drug may heighten the risk of contracting a rare and often fatal disease of the central nervous system.
	www.wtopnews.com /index.php?nid=111&sid=695728 (952 words)

	Biogen, IDEC merging in latest biotech pairing (printable version)
		BOSTON — Biogen and IDEC Pharmaceuticals, two companies looking for cures for cancer and autoimmune disorders, announced plans Monday to merge in a $6.4 billion stock swap, the latest consolidation in the biotech industry.
		IDEC shareholders would own 50.5 percent of the stock of the combined company, and Biogen shareholders the remaining 49.5 percent.
		Biogen shares were trading down $1.91, or more than 4 percent, at $41.89 in trading Monday afternoon on the Nasdaq Stock Market.
	www.rgj.com /news/printstory.php?id=45318 (461 words)

	ITworld.com - Biogen, Idec agree to merge in stock deal
		Biogen, with 2,700 employees worldwide, is based in Cambridge, Massachusetts, and Idec, with 1,000 employees globally, is in San Diego.
		Biogen has biological bulk manufacturing facilities in Cambridge and Research Triangle Park, North Carolina, and a large-scale manufacturing plant in Research Triangle Park to make bulk protein, which the company said is one of the largest cell culture facilities globally.
		Biogen is the world's oldest independent biotech, emerging out of a 1978 meeting of scientists including Phillip Sharp of the Massachusetts Institute of Technology and Walter Gilbert from Harvard University, both of whom are Nobel Prize winners.
	www.itworld.com /Tech/2428/030623biogen (772 words)

	ABC News: Biogen Idec 3Q Profit Falls 27 Percent (Site not responding. Last check: 2007-09-19)
		Cambridge-based Biogen Idec reported net income for the July-September period of $27.2 million, or 8 cents a share, compared with a profit of $36.8 million, or 10 cents per share, in last year's third quarter.
		Excluding those charges, Biogen Idec's profit totaled $122 million, or 36 cents per share, compared with a profit of $132 million, or 37 cents per share, excluding one-time expenses and gains a year ago.
		Biogen Idec announced earnings after its shares fell 41 cents to close at $40.01 on the Nasdaq Stock Market, where stock has traded in a 52-week range of $33.18 to $70.00.
	abcnews.go.com /Business/wireStory?id=1253024&CMP=OTC-RSSFeeds0312 (377 words)

	Genentech, Biogen Idec sued over Rituxan marketing North County Times - North San Diego and Southwest Riverside County ...
		Biogen Idec and Genentech have applied for FDA approval to market Rituxan as such a treatment, and a decision is expected by late February.
		While neither Genentech nor Biogen Idec are based in San Diego County, both companies have extensive ties to the local biotech industry.
		Biogen Idec was formed in 2003, when Idec merged with Biogen.
	www.nctimes.com /articles/2006/01/12/business/news/19_01_571_11_06.txt (872 words)

	ABC 7 News - Biogen Idec 4Q Profit Soars to $55.6M (Site not responding. Last check: 2007-09-19)
		Cambridge-based Biogen Idec reported net income for the October-December period of $55.6 million, or 16 cents per share, compared with a profit of $28.7 million, or 8 cents per share, in the same quarter a year ago.
		Biogen Idec said it expects its 2006 earnings excluding one-time items to fall in the range of $1.95 to $2.10 per share.
		Biogen Idec and Elan expect to hear back from the FDA late next month on an application they submitted last September to resume marketing Tysabri with a revised label and a plan to address patient risks.
	www.wjla.com /news/stories/0206/303155.html (544 words)

Try your search on: Qwika (all wikis)